Core Viewpoint - Sanofi Pharmaceutical (01530.HK) has successfully completed a placement agreement, issuing a total of 105,169,500 shares at a price of HKD 29.62 per share, representing approximately 4.14% of the enlarged issued share capital [1] Group 1: Placement Details - The placement was completed on December 9, 2025, with shares allocated to no fewer than six subscribers [1] - The net proceeds from the placement, after deducting commissions and related expenses, amount to approximately HKD 3.087 billion [2] Group 2: Use of Proceeds - Approximately 80% or HKD 2,469.47 million of the net proceeds will be allocated for research and development expenses, which include: - Advancing clinical studies for innovative drugs in China and the U.S. to accelerate pipeline progress, including but not limited to drugs 705 (PD1/HER2), 706 (PD1/PDL1), 008 (B7H3/IL15), 59 (MUC17/CD3/CD28), 626 (BDCA2), and 627 (TL1A) [2] - Supporting the expansion of indications for commercialized drugs or clinical trials outside of China to enhance product value and market coverage, including but not limited to TPO and EPO [2] - Building global infrastructure and supporting facilities [2] - Approximately 20% or HKD 617.37 million will be used for working capital and other general corporate purposes to support the group's ongoing operations and strategic plans [2]

Group 1 - The core point of the article is that Sangfor Technologies (01530.HK) has entered into a placement agreement with Morgan Stanley to issue approximately 105 million shares at a price of HKD 29.62 per share, representing about 4.32% of the total issued shares as of the announcement date [1] - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion [2] Group 2 - The company plans to use approximately 80% of the net proceeds for research and development expenses, which includes advancing clinical studies for innovative drugs in China and the U.S., supporting the expansion of indications for commercialized drugs, and building global infrastructure [2] - The remaining 20% of the net proceeds will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]

Core Viewpoint - The company, 3SBio (01530.HK), has announced a placement agreement with Morgan Stanley to issue approximately 105 million shares at a price of HKD 29.62 per share, representing about 4.32% of the total issued shares as of the announcement date [1] Group 1 - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion [2] - The company plans to use approximately 80% of the net proceeds for research and development expenses, which includes advancing clinical studies for innovative drugs in China and the U.S., supporting the expansion of indications for commercialized drugs, and building global infrastructure [2] - The remaining 20% of the net proceeds will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]

Group 1 - Company announced a placement agreement with an exclusive placement agent to issue 105 million shares at a price of HKD 29.62 per share, which represents a discount of 6.50% compared to the closing price of HKD 31.68 on the trading day prior to the agreement [1] - The placement shares will account for approximately 4.14% of the total issued shares after the placement, assuming no changes in the company's issued share capital from the announcement date until completion [1] Group 2 - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion after deducting placement commissions and other related expenses [2] - Approximately 80% of the net proceeds will be used for research and development, including advancing clinical studies for innovative drugs in China and the US, and supporting the expansion of indications for commercialized drugs [2] - The remaining 20% of the net proceeds will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]

Group 1 - The company, 3SBio (01530), has entered into a placement agreement with an exclusive placement agent to issue 105 million shares at a price of HKD 29.62 per share, which represents a 6.50% discount to the closing price of HKD 31.68 prior to the agreement [1] - The placement shares will account for approximately 4.14% of the total issued shares after the placement, assuming no changes in the company's issued share capital from the announcement date until completion [1] Group 2 - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion after deducting placement commissions and other related expenses [2] - The company plans to allocate approximately 80% of the net proceeds for research and development expenses, which includes advancing clinical studies for innovative drugs in China and the U.S., supporting indication expansions for commercialized drugs, and building global infrastructure [2] - The remaining 20% of the net proceeds will be used for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]